Callodine Capital Management’s GSK GSK Stock Holding History

Callodine Capital Management’s Portfolio GSK Stock Details GSK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$51.4M	Sell	979,740 -279,737	-22%	-$14.8M	3.35%	9
2026 Q1	$69.5M	Buy	1,259,477 +255,150	+25%	+$13.8M	4.86%	4
2025 Q4	$49.3M	Buy	1,004,327 +302,276	+43%	+$14.1M	3.96%	8
2025 Q3	$30.3M	Buy	702,051 +103,532	+17%	+$4.04M	2.65%	13
2025 Q2	$23M	Buy	598,519 +28,519	+5%	+$1.09M	2.38%	16
2025 Q1	$22.1M	Sell	570,000 -130,000	-19%	-$4.76M	3.67%	11
2024 Q4	$23.7M	Buy	700,000 +95,000	+16%	+$3.42M	4.89%	5
2024 Q3	$24.7M	Buy	605,000 +65,000	+12%	+$2.66M	5.16%	6
2024 Q2	$20.8M	Buy	540,000 +140,000	+35%	+$5.89M	4.85%	5
2024 Q1	$17.1M	Sell	400,000 -50,000	-11%	-$2.06M	4.15%	10
2023 Q4	$16.7M	Sell	450,000 -25,000	-5%	-$897K	4.39%	7
2023 Q3	$17.2M	Buy	475,000 +25,000	+6%	+$887K	4.8%	6
2023 Q2	$16M	Hold	450,000	–	–	4.61%	8
2023 Q1	$16M	Buy	450,000 +240,000	+114%	+$8.4M	4.72%	9
2022 Q4	$7.38M	Buy	+210,000	New	+$6.99M	2.2%	17

Other funds holding GSK

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

JEST

JTC Employer Solutions Trustee St Helier, Jersey $1.25B AUM 41.83% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Callodine Capital Management's GSK Position: Q2 2026 in Review

Callodine Capital Management reduced its GSK (GSK) stake by 22% in Q2 2026, selling an estimated $14.8M and leaving 979,740 shares worth $51.4M. The position accounts for 3.35% of the portfolio, ranked #9.

Callodine Capital Management first reported a position in GSK in Q4 2022 and has held it in 15 quarters since. The position peaked at $69.5M in Q1 2026. 1,037 funds tracked by Wall St. Rank hold GSK as of Q2 2026.

Callodine Capital Management held 979,740 shares of GSK worth $51.4M as of Q2 2026.
Callodine Capital Management sold 279,737 GSK shares in Q2 2026, an estimated $14.8M.
GSK made up 3.35% of Callodine Capital Management's portfolio in Q2 2026, its #9 holding.
Callodine Capital Management first reported a position in GSK in Q4 2022 and has held it in 15 quarters since.
Callodine Capital Management's GSK position peaked at $69.5M in Q1 2026.
1,037 funds tracked by Wall St. Rank held GSK as of Q2 2026.

Based on Callodine Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.